INSTITUT PASTEUR Multiple myeloma is a cancer of the bone marrow, with a life expectancy of less than 5 years post-diagnosis. Proteasome inhibitors, the therapeutic backbone of current treatments, are very effective in treating newly diagnosed cancers but resistance or intolerance to these molecules inevitably develop, leading to relapses. While studying a neglected tropical disease,...
Tag: <span>novel therapeutic target</span>
Post
Glioblastoma study discovers protective role of metabolic enzyme, revealing a novel therapeutic target
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER IMAGE: FROM LEFT TO RIGHT: FRANCESCA PUCA, PH.D., ANDREA VIALE, M.D., AND GIULIO DRAETTA, M.D., PH.D. CREDIT: MD ANDERSON CANCER CENTER HOUSTON – Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel function for the metabolic enzyme medium-chain acyl-CoA dehydrogenase (MCAD) in glioblastoma (GBM)....